Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Download Data

Icosavax Inc Free Cash Flow for the year ending December 31, 2022: USD -72.79 M

Icosavax Inc Free Cash Flow is USD -72.79 M for the year ending December 31, 2022, a -84.06% change year over year. Free Cash Flow is the cash flow available to a company after deducting capital expenditures from operating cash flow, indicating its ability to generate cash for expansion, debt repayment, or dividends.

Icosavax Inc Free Cash Flow for the year ending December 31, 2021 was USD -39.55 M, a -178.12% change year over year.
Icosavax Inc Free Cash Flow for the year ending December 31, 2020 was USD -14.22 M, a -211.21% change year over year.
Icosavax Inc Free Cash Flow for the year ending December 31, 2019 was USD -4.57 M.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends